Dr. Adelaide Robb, MD
Neurology (Clinical Neurophysiology Physician)
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Neurophysiology Physician primary
DC license MD18640
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital (212 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 17 payments worth $10,671 in total to this clinician.
| Supernus Pharmaceuticals, Inc. | $9,013 |
|---|---|
| Axsome Therapeutics, Inc. | $1,500 |
| Neurelis, Inc. | $123 |
| Janssen Research & Development, LLC | $34.53 |
| Honoraria | $7,410 |
|---|---|
| Consulting Fee | $1,500 |
| Travel and Lodging | $1,403 |
| Food and Beverage | $358 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. Dec 4, 2025 | Honoraria Qelbree · VILOXAZINE HYDROCHLORIDE | $7,410 |
| Axsome Therapeutics, Inc. Sep 17, 2025 | Consulting Fee | $1,500 |
| Supernus Pharmaceuticals, Inc. Dec 4, 2025 | Travel and Lodging Qelbree · VILOXAZINE HYDROCHLORIDE · travel to Naples, FL · in-kind | $590 |
| Supernus Pharmaceuticals, Inc. Dec 4, 2025 | Travel and Lodging Qelbree · VILOXAZINE HYDROCHLORIDE · travel to Fort Myers, FL · in-kind | $374 |
| Supernus Pharmaceuticals, Inc. Dec 4, 2025 | Travel and Lodging Qelbree · VILOXAZINE HYDROCHLORIDE · travel to Naples, FL · in-kind | $299 |
| Supernus Pharmaceuticals, Inc. Dec 4, 2025 | Travel and Lodging Qelbree · VILOXAZINE HYDROCHLORIDE · travel to Naples, FL · in-kind | $141 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $191,943 in research payments for these studies, mostly to the institutions running them.
- Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Acadia Pharmaceuticals Inc · Completed · NCT05523895 - Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Acadia Pharmaceuticals Inc · Terminated · NCT05555615 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Alkermes, Inc. · Enrolling by invitation · NCT04987229 - Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc. · Recruiting · NCT05303064
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.